MINNEAPOLIS, June 13, 2011 /PRNewswire/ -- Uroplasty, Inc.
(NASDAQ: UPI), a medical device company that develops, manufactures
and markets innovative proprietary products to treat voiding
dysfunctions, today announced it has been included on a list of
preliminary additions to the Russell 3000® Index and the Russell Global®
Index posted by Russell Investments on June
10, 2011 on www.russell.com. These changes are expected to
go into effect after the close of trading on Friday, June 24, 2011.
"The preliminary addition of Uroplasty to the Russell 3000 and Russell Global indexes is a
testament to the progress we have made in building valuation," said
David Kaysen, president and CEO of
Uroplasty. "It should help expand awareness of our company,
especially among institutional investors, as we continue to execute
our growth strategy for our Urgent PC® and Macroplastique® product
lines."
The Russell 3000 Index measures
the performance of the largest 3000 U.S. companies, representing
approximately 98% of the investable U.S. equity market. The Russell
Global Index measures the performance of the global equity market
based on all investable equity securities, and includes
approximately 10,000 securities in 48 countries and covers 98% of
the investable global market. The Russell indexes are widely used by investment
managers and institutional investors for index funds and as
benchmarks for passive and active investment strategies. The
indexes are reconstituted annually.
About Uroplasty, Inc.
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned
subsidiaries in The Netherlands
and the United Kingdom, is a
medical device company that develops, manufactures and markets
innovative proprietary products for the treatment of voiding
dysfunctions. Our focus is the continued commercialization of our
Urgent® PC Neuromodulation System, the only FDA-cleared system that
delivers posterior tibial nerve stimulation (PTNS) for the
office-based treatment of overactive bladder and associated
symptoms of urgency, frequency and urge incontinence. We also offer
Macroplastique® Implants, an injectable urethral bulking agent for
the treatment of adult female stress urinary incontinence primarily
due to intrinsic sphincter deficiency. For more information on the
company and its products, please visit Uroplasty, Inc. at
www.uroplasty.com.
For Further
Information:
Uroplasty, Inc.
David Kaysen, President and CEO,
or
Medi Jiwani, Vice President,
CFO, Treasurer
952.426.6140
|
EVC Group
Doug Sherk/Jenifer Kirtland
(Investors), 415.896.6820
Chris Gale (Media),
646.201.5431
|
|
|
|
SOURCE Uroplasty, Inc.